Everolimus vs Mycophenolate Mofetil in Heart TransplantationEverolimus vs Mycophenolate Mofetil in Heart Transplantation
In an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to everolimus 1.5 mg or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil 3 g/day with standard-dose cyclosporine. American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2013 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news
Cyclosporine May Be an Option in Allergic ConjunctivitisCyclosporine May Be an Option in Allergic Conjunctivitis
Topical cyclosporine may spare patients the adverse effects associated with corticosteroids, investigators say. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Infliximab Better Than Cyclosporine in Refractory ColitisInfliximab Better Than Cyclosporine in Refractory Colitis
Infliximab appears to be better than cyclosporine as salvage therapy for steroid-refractory acute severe ulcerative colitis (UC), researchers from Australia report. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
New Automated Immunosuppressive Drug Assays Improve Therapeutic Drug Monitoring for Transplant Patients
For the first time, certain immunosuppressive drug (ISD) assays can now be performed automatically on cobas® modular platforms, allowing laboratories to consolidate testing for a wide range of transplant testing/monitoring assays onto a single platform. The new Roche automated assays for tacrolimus and cyclosporine will enhance therapeutic drug monitoring (TDM) of transplant recipients by providing the consistency and accuracy of an automated assay, while enhancing workflows, auditing and reporting capabilities in the laboratory. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - July 2, 2013 Category: Pharmaceuticals Source Type: news
600th Heart Attack Patient Recruited Into Phase III CicloMulsion® CIRCUS Trial
NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion® (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heart reperfusion injury following stenting in patients with myocardial infarction... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 27, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news
Abuse of Opana ER (oxymorphone) associated with thrombotic thrombocytopenic purpura
3.5 out of 5 stars
Thrombotic Thrombocytopenic Purpura (TTP)-Like Illness Associated with Intravenous Opana ER Abuse — Tennessee, 2012. MMWR 2013 Jan 11;62:1-4.
Full Text
This paper describes a 2012 CDC investigation into a cluster of 15 cases of thrombotic thrombocytopenic purpura (TTP)-like illness in the state of Tennessee. TTP-like illness was defined as microangiopathic hemolytic anemia (hemolytic anemia anemia based on haptoglobin and lactate dehydrogenase with schistocytes and an admission platelet count < 50,000/μL. Typical TTP-like signs and symptoms included nausea (11 patients), abdominal pain (11), f...
Source: The Poison Review - January 15, 2013 Category: Toxicology Authors: Leon Tags: Medical opana oxymorphone thrombotic thrombocytopenic purpura ttp Source Type: news
Acute Calcineurin Inhibitor Overdose: Analysis of Cases Reported to a National Poison Center Between 1995 and 2011 - Ceschi A, Rauber-Lüthy C, Kupferschmidt H, Banner NR, Ansari M, Krähenbühl S, Taegtmeyer AB.
This study investigated the circumstances, pharmacokinetics and outcomes of overdose with cyclosporine ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - January 6, 2013 Category: Global & Universal Tags: Home and Consumer Product Safety Source Type: news
After liver transplant for HCV, better antiviral results with cyclosporine
NEW YORK (Reuters Health) - In patients transplanted for hepatitis C cirrhosis, the virus inevitably
recurs. Now a new meta-analysis suggests that cyclosporine-based immunosuppression may be associated with a better
response to antiviral therapy after transplant than tacrolimus-based protocols. (Source: Modern Medicine)
Source: Modern Medicine - January 2, 2013 Category: Journals (General) Source Type: news
UPDATE: After liver transplant for HCV, better antiviral results with cyclosporine
NEW YORK (Reuters Health) - In patients transplanted for hepatitis C cirrhosis, the virus inevitably
recurs. Now a new meta-analysis suggests that cyclosporine-based immunosuppression may be associated with a better
response to antiviral therapy after transplant than tacrolimus-based protocols. (Source: Modern Medicine)
Source: Modern Medicine - January 2, 2013 Category: Journals (General) Source Type: news
